comparemela.com

Latest Breaking News On - Novavax influenza program - Page 2 : comparemela.com

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage companyReiterating.

South koreaSouth africaNew zealandUnited kingdomUnited arab emiratesGreat britainStanleyc erckAlison chartanNational institute of allergyPrnewswire novavax incVaccine clinical developmentAdvisory committeeTakeda pharmaceutical companyCoalition for epidemic preparedness innovationsEuropean unionSerum institute

Initial Results from Novavax COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC combines Novavax' COVID-19 vaccine .

United statesGregorym glennWorld health organizationEuropean commissionDrug administrationWorld vaccine congressExchange commissionNovavax influenza programSerum instituteInfluenza programNovavax incInfluenza combination vaccineLancet authorizationImportant safety informationProduct characteristicsPackage leaflet

Novavax, Inc : Initial Results from Novavax COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenicData from this combination trial will inform planned Phase 2 dose

United statesLaura keenan lindseyErika schultzGregorym glennAli chartanWorld health organizationEuropean commissionDrug administrationPrnewswire novavax incWorld vaccine congressExchange commissionNovavax influenza programInfluenza programSerum institute of indiaNovavax incInfluenza combination vaccine

Initial Results from Novavax COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

/PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious.

United statesLaura keenan lindseyErika schultzGregorym glennAli chartanWorld health organizationEuropean commissionDrug administrationWorld vaccine congressExchange commissionNovavax influenza programInfluenza programSerum institute of indiaNovavax incInfluenza combination vaccineSafety information

vimarsana © 2020. All Rights Reserved.